Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

In a remarkable display of market confidence, Verona Pharma (NASDAQ:VRNA)'s stock has surged to an all-time high, reaching a ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

Verona Pharma (NASDAQ:VRNA – Get Free Report) was upgraded by investment analysts at Roth Capital to a “strong-buy” rating in a report released on Friday,Zacks.com reports. A number of other equities ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Verona Pharma plc (NASDAQ:VRNA – Free Report) – HC Wainwright raised their Q1 2025 earnings estimates for shares of Verona Pharma in a report issued on Tuesday, January 21st. HC Wainwright ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Verona Pharma. Looking at options history for Verona Pharma (NASDAQ:VRNA) we detected 14 trades. If we consider the ...

Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions ...